-
Over 70 Chinese new drug research and development companies completed financing in the first quarter. These therapies are attracting attention
Time of Update: 2021-05-09
focus on gene therapy; Meizhi Pharmaceutical is committed to using PROTAC technology to develop protein degradation therapies; Yilian Bio is developing a new generation of ADC; Zhongmei Ruikang focuses on the development of small Activate RNA drugs; Junsai Bio is committed to developing innovative treatments for solid tumors based on tumor infiltrating lymphocytes (TIL); Jiachen Xihai is developing innovative RNA drugs, etc.
-
The long-acting GLP-1 hypoglycemic drug "Semaglutide Injection" is about to be approved
Time of Update: 2021-05-09
From: NMPA; the review time axis is attached at the end of the articleSemaglutide injection (Semaglutide, English trade name: Ozempic) is a long-acting GLP-1 receptor agonist developed by Novo Nordisk.
-
Henri Carrelizumab is about to be approved for new indications for nasopharyngeal carcinoma
Time of Update: 2021-05-09
The trial included 156 patients with recurrent/metastatic nasopharyngeal carcinoma who had failed ≥2 lines of treatment.
Among the domestically approved PD-1s, only Hengrui and Junshi have reported on the market for nasopharyngeal cancer indications, including third-line and first-line treatments for nasopharyngeal cancer.
-
National Medical Insurance Administration: Establishing a sound medical insurance outpatient mutual aid guarantee mechanism
Time of Update: 2021-05-09
At the State Council’s policy briefing held recently by the State Council Information Office, Chen Jinfu, deputy director of the National Medical Insurance Administration, stated that the State Council’s executive committee had previously reviewed and approved the “Regarding the Establishment and Improvement of the Employee Basic Medical Insurance Outpatient Mutual Aid Guarantee Mechanism "Guiding Opinions", the document has been issued by the General Office of the State Council.
-
Medical and health legal experts talk about "tumor treatment shady" Excessive medical treatment is illegal
Time of Update: 2021-05-09
Zheng Xueqian believes that the important value of Zhang Yu's article exposing the "shadow of tumor treatment" is to make the country pay attention to this matter and standardize tumor treatment, while also reminding doctors of self-discipline.
-
The test failed!
Time of Update: 2021-05-08
Compile Ke KeA few days ago, Novartis quietly revealed in its first quarter 2021 financial report that the Phase 3 clinical trial Paradise-MI showed that Entresto missed the primary endpoint of reducing the risk of cardiovascular death and heart failure after acute myocardial infarction.
-
Hengrui Medicine's SHR-A1904 for injection was approved for clinical use in the treatment of advanced solid tumors
Time of Update: 2021-05-08
has recently received the approval of the State Food and Drug Administration to issue the "Drug Clinical Trial Approval Notice" on SHR-A1904 for injection, which will be used in the near future.
This product is an antibody-drug conjugate targeting tumor-specific antigens.
-
2021 prediction: these 10 drugs sell best (list attached)
Time of Update: 2021-05-08
In the PD-1 battle, K medicine won a key victory in the battle for the first-line lung cancer treatment with O medicine, and achieved a counterattack: In 2016, the sales of O medicine were nearly three times that of K medicine; in 2020, K medicine sales The amount is close to 15 billion US dollars, which is nearly twice the sales of O medicine.
-
The average number of anti-tumor negotiation drugs in Chinese hospitals increased by 15%
Time of Update: 2021-05-08
" Hejie said that in the future, the National Cancer Center will continue to monitor the clinical application of anti-tumor drugs, analyze, evaluate and improve the use of key drugs, and better guide the clinical rational deployment and use of anti-tumor drugs, and contribute to the national health.
-
Hengrui Medicine's iodixanol injection passed the consistency evaluation
Time of Update: 2021-05-08
In 2001, iodixanol injection (trade name: Weishi Parker) was approved to be imported and marketed by the State Food and Drug Administration.
Among them, Yangzijiang Pharmaceutical, Chia Tai Tianqing Pharmaceutical, and Shanghai Stellite have passed (or regarded as Pass) Consistency evaluation of generic drugs.
-
Three independent directors of Jiaying Pharmaceutical resign after their term of office expires
Time of Update: 2021-05-08
On April 28, Jiaying Pharmaceutical issued an announcement stating that on April 26, 2021, it received letters of resignation from the company’s independent directors, Mr.
Fang Xiaobo did not directly hold the company’s shares, and there were no unfulfilled commitments that should be fulfilled.
-
Without it, there would be no mRNA new crown vaccine lipid nanoparticle technology ushered in a "renaissance"
Time of Update: 2021-05-08
The mRNA-based new coronavirus vaccine was able to be successful less than a year after the release of the new coronavirus genome sequence, thanks to the decades-long efforts of researchers in lipid nanoparticle (LNP) delivery technology.
org/pharmaceuticals/drug-delivery/Without-lipid-shells-mRNA- vaccines/99/i8[2] Let's talk about lipid nanoparticles.
-
Good news for patients with eye allergy and dry eye disease!
Time of Update: 2021-05-08
Today, Aldeyra Therapeutics announced that its investigational therapy reproxalap eye drops reached the primary endpoint and all secondary endpoints in the Phase 3 clinical trial INVIGORATE for the treatment of patients with allergic conjunctivitis, significantly reducing itching, redness and tearing of the eyes caused by allergies.
-
The output of bergamot has dropped continuously, is the market rising continuously?
Time of Update: 2021-05-08
Medicine Net, April 29, news of bergamot, a variety with a historical price of 400 yuan, the market has been sluggish for the past ten years.
Medicine Net, April 29, news of bergamot, a variety with a historical price of 400 yuan, the market has been sluggish for the past ten years.
-
Experts from all parties call for the effectiveness of a multi-level medical security system
Time of Update: 2021-05-08
Lou Hong, Dean of the National Medical Security Research Institute of Capital Medical University, pointed out that the development of a multi-level medical security system requires a new pattern of joint construction, co-governance, and shared medical insurance governance.
-
ASM Biotech declares the third domestic CD20/CD3 double antibody
Time of Update: 2021-05-08
6% (n=32/62) of r/r FL patients who received mosunetuzumab have achieved complete remission (CR), and mosunetuzumab is currently being developed globally Phase III clinical trials have been approved in China.
-
Cinda ophthalmic drug IBI302 Phase II clinical completed the first patient administration
Time of Update: 2021-05-08
In the ongoing phase II clinical study, in addition to evaluating the efficacy of IBI302 in improving vision and retinal thickness, it will also focus on its potential improvement effect on macular atrophy and fibrosis.
-
A company that has stopped supplying raw materials refuses to fulfill its obligation of selection in centralized procurement
Time of Update: 2021-05-08
Text | Wind HillOn April 26, the Zhejiang Pharmaceutical Equipment Procurement Center issued an announcement stating that the cefmetazole sodium for injection produced by Suzhou Dawnrays Pharmaceutical Co.
-
New tumor target METTL3, potential first-in-class leukemia new drug appears
Time of Update: 2021-05-08
In vivo studies have shown that STM2457 can prevent the expansion of AML and reduce key leukemia stem cells (Source: Nature)Collectively, these results reveal that METL3 inhibition can be used as a potential therapeutic strategy for anti-AML, and provide a proof of concept for targeting RNA-modifying enzymes as a promising new approach to anti-cancer therapy.
-
Eli Lilly terminates development of psoriasis drug mirikizumab
Time of Update: 2021-05-08
CompilationFan DongdongA few days ago, Eli Lilly said it would abandon the regulatory application for mirikizumab to treat psoriasis, although this IgG4 monoclonal antibody performed better than Novartis’ Cosentyx in last year’s phase 3 trial.
